1. Effectiveness, safety and T-cell activation profiles of long-term Myrcludex B treatment in two patients with HDV related compensated cirrhosis. (February 2019) Authors: Loglio, A.; Alexandrov, A.; Renteria, S.C. Uceda; Tham, C.Y.L.; Greco, L.; Borghi, M.; Perbellini, R.; Trombetta, E.; Giovanelli, S.; Porretti, L.; Lecchi, L.; Prati, D.; Ceriotti, F.; Lunghi, G.; Bertoletti, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and efficacy of up to 76 weeks 10 mg/day (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis. (February 2020) Authors: Loglio, A.; Ferenci, P.; Schlund, F.; Tham, C.Y.L.; van Bömmel, F.; Renteria, SC. Uceda; Borghi, M.; Holzmann, H.; Perbellini, R.; Trombetta, E.; Giovanelli, S.; Porretti, L.; Prati, D.; Ceriotti, F.; Lunghi, G.; Bertoletti, A.; Urban, S.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗